
INNOVATION
Pipeline
OnQuality Pharmaceuticals is pioneering the field of targeted supportive cancer therapies. Our lead compound is an oncodermatology hand and foot ointment called OQL011, which is being evaluated for the treatment of Hand-Foot Skin Reaction, currently enrolling in Phase 2 clinical trials. We also have several pre-clinical assets that will enter clinical trials in the near future. Additionally, we have two promising assets that are in the early discovery stage targeting oncogastroenterology conditions.
Therapeutic indication
Discovery
IND
Phase I
Phase II
Phase III
OQL011
VEGFR Inhibitor-induced hand-foot skin reaction
OQL012
VEGFR Inhibitor-induced hand-foot skin reaction